Q-omics provides the consensus-scored CTBP1-AS profile across patient tissues and cancer cell-line models. CTBP1-AS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CTBP1-AS is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CTBP1-AS RNA expression shows 19,488 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where CTBP1-AS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTBP1-AS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTBP1-AS survival associations across molecular data types. CTBP1-AS RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTBP1-AS RNA expression–survival associations across cancer types. High CTBP1-AS expression shows unfavorable associations in UVM and CESC, but favorable associations in HNSC, SKCM, UCS and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CTBP1-AS RNA expression.
This table summarizes CTBP1-AS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CTBP1-AS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTBP1-AS shows lower tumor expression in BRCA and higher tumor expression in KIRC, LIHC, STAD, COAD and KICH. The KIRC box plot shows higher CTBP1-AS RNA expression in tumor versus normal tissue (log2 FC = +0.206, t-test p < 0.001).
This table shows molecular features associated with CTBP1-AS in patient tissues and cancer cell lines. In patient samples, CTBP1-AS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
